Denosumab in Subjects With Giant Cell Rich Tumors of Bone

Inclusion Criteria: * Pathologically proven giant cell rich tumor: * Aneurysmal bone cysts (ABC) * Giant cell granuloma (GCG) * Other giant cell rich lesions (primary bone, non-malignant, pathology and radiology to be reviewed during multidisciplinary meeting LUMC) * Patients with surgically unsalvageable disease (e.g., sacral, spinal giant cell rich tumors, or multiple lesions including pulmonary metastases) OR patients whose planned surgery includes joint resection, limb amputation, hemipelvectomy or surgical procedure resulting in severe morbidity * Measurable evidence of active disease within 1 year before study enrollment * Albumin-adjusted serum calcium level ≥ 2.0 mmol/L (8.0 mg/dL) * Aged 18 years and up and skeletally mature * ECOG performance status 0, 1 or 2 * Written signed informed consent Exclusion Criteria: * Known or suspected current diagnosis of classic GCTB * Known or suspected current diagnosis of underlying malignancy including but not limited to high-grade sarcoma, osteosarcoma, fibrosarcoma, malignant giant cell sarcoma * Known or suspected current diagnosis of brown cell tumor of hyperparathyroidism, Paget's disease or cherubism * Known or suspected current diagnosis of primary soft tissue tumor with invasion of the bone * Known diagnosis of other malignancy within the past 5 years (patients with definitively treated basal cell carcinoma and cervical carcinoma in situ are permitted) * Previous treatment with denosumab (with the exception of p…